That might be able to guide the need for some individuals to consider newer therapies, which are more potent, in the future, he said
Ongoing Support and Monitoring: Regular follow-up visits to track your progress, discuss any challenges, and adjust your plan as needed
Tirzepatide: It activates both GLP-1 and Glucose-dependent Insulinotropic Polypeptide (GIP) receptors
This glucose-dependent safety profile is a major advantage over older glucose-lowering agents like sulfonylureas
Most patients notice appetite reduction and changes in food preferences within the first one to two weeks, even at the 2.5mg starter dose
Meier JJ, Rosenstock J, Hincelin-Mery A et al (2015) Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial